Chardan Capital Reiterates Buy Rating for Orchestra BioMed (NASDAQ:OBIO)
Orchestra BioMed (NASDAQ:OBIO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a report released on Tuesday,Benzinga reports. They currently have a $20.00 price objective on the stock. Other analysts have also issued reports about the stock. B. Riley upgraded shares of Orchestra BioMed to a “strong-buy” […]
Orchestra BioMed (NASDAQ:OBIO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a report released on Tuesday,Benzinga reports. They currently have a $20.00 price objective on the stock. Other analysts have also issued reports about the stock. B. Riley upgraded shares of Orchestra BioMed to a “strong-buy” […]
